United Therapeutics (CIK 1452866) filed its 2024 10-K Item 1C disclosing no material cybersecurity incidents to date. The filing details a robust governance structure involving an Audit Committee and Incident Management Team (IMT), a risk-based strategy aligned with NIST, and a five-phase incident response process (Identify, Protect, Detect, Respond, Recover). The company maintains cyber liability insurance and has not experienced any incidents materially impacting operations or financial condition.